title: [In Process Citation].
abstract: Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2015, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2015, 156(Suppl. 1), 25-35.
authors.affiliation: 1 Budai Hepatológiai Centrum Budapest Egry József u. 1-3. 1111.
authors.forename: Gábor
authors.initials: G
authors.lastname: Horváth
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Gerlei
authors.forename: Judit
authors.initials: J
authors.lastname: Gervain
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lengyel
authors.forename: Mihály
authors.initials: M
authors.lastname: Makara
authors.forename: Alajos
authors.initials: A
authors.lastname: Pár
authors.forename: László
authors.initials: L
authors.lastname: Rókusz
authors.forename: Ferenc
authors.initials: F
authors.lastname: Szalay
authors.forename: László
authors.initials: L
authors.lastname: Telegdy
authors.forename: István
authors.initials: I
authors.lastname: Tornai
authors.forename: Klára
authors.initials: K
authors.lastname: Werling
authors.forename: Béla
authors.initials: B
authors.lastname: Hunyady
keywords: adefovir; cirrhosis; entecavir; hepatitis B virus; hepatitis B-vírus; hepatitis D virus; hepatitis D-vírus; interferon; lamivudin; lamivudine; liver cancer; májrák; májzsugor; pegilált interferon; pegylated interferon; tenofovir; viral hepatitis; vírushepatitis